Author Affiliations: Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Md.
One of every 6 men living in the United States will be diagnosed with
prostate cancer at some point in his life.1 Although
the likelihood of death from such a diagnosis is much less than 1 in 6, nearly
30 000 men will die from prostate cancer this year.1 Many
men who die from this disease were originally diagnosed with clinically significant
tumors, which were palpable, of an intermediate to high grade on review of
the needle biopsy specimen, and/or associated with a serum prostate specific
antigen (PSA) of more than 10 ng/mL.2,3 The
10-year disease-free survival following surgical or nonsurgical therapy for
such men is frequently less than 50%.4
DeWeese TL. Radiation Therapy and Androgen Suppression as Treatment for Clinically Localized Prostate Cancer: The New Standard? JAMA. 2004;292(7):864–866. doi:10.1001/jama.292.7.864
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: